. 2014 Oct 10;5(4):646–659. doi: 10.5306/wjco.v5.i4.646

Table 2.

Quality of life assessment (first-generation epidermal growth factor receptor-tyrosine kinase inhibitors vs chemotherapy)

Study	Treatment	Method^a
		FACT-L	P^b	TOI		LCS	P
IPASS[7]	Gefitinib	70.2%	< 0.0001	70.2%	< 0.0001	75.6%	0.000
IPASS[7]	CBDCA + PTX	44.5%	< 0.0001	38.3%	< 0.0001	53.9%	0.000
OPTIMAL[13]	Erlotinib	74.3%	< 0.0001	73%	< 0.0001	77%	< 0.0001
OPTIMAL[13]	CBDCA + GEM	31.5%	< 0.0001	25.9%	< 0.0001	31.5%	< 0.0001

Evaluable for quality of life population; logistic regression model with covariates;

6-point improvement (FACT-L and TOI); 2-point improvement (LCS), maintained ≥ 21 d. EGFR-TKIs: Epidermal growth factor receptor tyrosine kinase inhibitors; FACT-L: Functional assessment of cancer therapy–lung; TOI: Trial outcome index; LCS: Lung cancer subscale; CBDCA: Carboplatin; PTX: Paclitaxel; GEM: Gemcitabine.